upsid revenu big ep beat
focu turn reiter buy
strong even adjust pull-forward ep ahead
sale yoy vs consensu
result broadli higher expect everi segment class sequenc instrument
yoy array yoy sequenc consum
yoy note stock order chines custom
get ahead potenti tariff action follow similar move driven
mix gross margin particularli strong vs estimate opm
ahead well cost control volum vs estimate non-gaap
ep vs our/street est beat yoy
surpris look longer term runway
overal quarter came larg expect end-market show
steadi solid demand includ posit trend popul sequenc
custom consum genom clinic oncolog largest diverg
estim came strong seq instrument perform despit concern
investor due mix mid-quart channel check well continu pull-
forward seq consum management note tariff place good
levi instrument seen chang buy pattern
result consum order time like precautionari move
look ahead expect modest flat slightli revenu given stock
focu turn area potenti upsid given healthi demand
earli stage novaseq product cycl think ilmn perform
bode well next year outlook estimate sale growth sizeabl oper
leverag addit option balanc sheet cash
revenu estim mostli unchang see significantli higher earn
power ep overal bullish
reiter buy rate sequenc demand clearli continu grow across end-
market custom maintain po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit prospect due wide
adopt compani innov genet
analysi tool strong competit posit
impress forward-look product market
strategi although macro competit risk
remain believ compani recent
launch near-term pipelin help
remain forefront
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim consid
justifi given attract long-term outlook genom market compani
technolog leadership new product cycl increas penetr fast-
grow clinic appli market
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit integr
issu grow concern data privaci slower-than-expect uptak new
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
